HeimABBV34 • BVMF
add
Abbvie Inc BDR
Við síðustu lokun
62,90 R$
Dagbil
62,90 R$ - 63,90 R$
Árabil
54,36 R$ - 79,10 R$
Markaðsvirði
322,03 ma. USD
Meðalmagn
5,63 þ.
Í fréttum
TipRanks
fyrir 2 dögum
AbbVie’s Linaclotide Study: A Potential Breakthrough for Pediatric Constipation
2,40%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 13,34 ma. | 8,39% |
Rekstrarkostnaður | 5,28 ma. | 8,44% |
Nettótekjur | 1,29 ma. | -6,06% |
Hagnaðarhlutfall | 9,64 | -13,31% |
Hagnaður á hvern hlut | 2,46 | 6,49% |
EBITDA | 6,10 ma. | 11,89% |
Virkt skatthlutfall | 22,40% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 5,18 ma. | -71,35% |
Heildareignir | 136,16 ma. | -8,54% |
Heildarskuldir | 134,70 ma. | -4,35% |
Eigið fé alls | 1,46 ma. | — |
Útistandandi hlutabréf | 1,77 ma. | — |
Eiginfjárgengi | 78,62 | — |
Arðsemi eigna | 7,48% | — |
Ávöxtun eigin fjár | 14,21% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 1,29 ma. | -6,06% |
Handbært fé frá rekstri | 1,64 ma. | -59,53% |
Reiðufé frá fjárfestingum | -735,00 m. | 92,33% |
Reiðufé frá fjármögnun | -1,26 ma. | -111,63% |
Breyting á handbæru fé | -349,00 m. | -106,64% |
Frjálst peningaflæði | 1,12 ma. | -73,12% |
Um
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. Its major products are: Humira, approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis and administered via injection; Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases; Rinvoq, used to treat arthritis; and Botox. Its other major products include Imbruvica to treat cancer, Vraylar to treat schizophrenia and bipolar disorder, Venclexta to treat leukemia and lymphoma, Mavyret to treat Hepatitis C, and Epkinly, a blood-cancer therapy developed in partnership with Genmab. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev and tavapadon.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. Wikipedia
Stofnsett
10. apr. 2012
Höfuðstöðvar
Vefsvæði
Starfsfólk
55.000
